scispace - formally typeset
M

Michael B. Sporn

Researcher at Dartmouth College

Publications -  561
Citations -  96644

Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.

Papers
More filters
Patent

Therapeutic compositions and methods of use

TL;DR: In this article, the authors present a list of compounds and methods useful for chemopreventive treatment of diseases such as cancer, Alzheimer's disease, Parkinson disease, inflammatory bowel diseases and multiple sclerosis.
Patent

Methods for Using Synthetic Triterpenoids in the Treatment of Bone or Cartilage Diseases or Conditions

TL;DR: In this paper, the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions is described.
Journal ArticleDOI

A binding assay for the solubilized receptors of type beta transforming growth factor: adsorption and removal of free ligand by dextran-coated charcoal.

TL;DR: This method can assay receptors from purified membranes and crude extracts of cells and tissues, and was used to demonstrate that TGF-beta receptors are glycosylated and retain a high affinity (Kd approximately 530 pM) for ligand after solubilization.
Journal ArticleDOI

Dihydroretinoic acids and their derivatives. synthesis and biological activity

TL;DR: Aufgrund der Wirkung von Retinsaure-Derivaten gegen Hautkrebs werden die analogen Verbindungen (I)-(V) hergestellt und untersucht, wobei verschiedene der Dihydroverbindungen eine gewisse Aktivitat zeigen.
Journal ArticleDOI

Immunohistochemical Localization of TGFβ2 and β3 in the Nervous System

TL;DR: Synthetic peptides corresponding to regions of human TGFP2 and chicken TGFP3 were coupled to bovine serum albumin through added amino and carboxyl terminal tyrosines and the conjugates were injected into rabbits to produce polyclonal antisera.